Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services globally, operating in the United States, Europe, Canada, the Asia Pacific, and other international markets. The company is structured into three main segments. The Research Models and Services segment produces and sells rodents, including purpose-bred rats and mice, for research use. This segment also offers services supporting research models, such as genetically engineered models and services, insourcing solutions, and research animal diagnostic services, and is involved in the development and production of cell therapies. The Discovery and Safety Assessment segment provides in vitro and in vivo discovery services for novel drugs, molecule compounds, oligonucleotides, biotherapeutics, and antibodies, delivering preclinical candidates for safety assessment. It also offers safety assessment services, including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics, alongside vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized biologics testing outsourced by pharmaceutical and biotechnology companies, and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles for its contract development and manufacturing organization, and a strategic alliance with Francis Crick Institute (Crick), Inc. for Antibody-Drug Conjugate (ADC) drug discovery and development. Founded in 1947, Charles River Laboratories International, Inc. is headquartered in Wilmington, Massachusetts.